澳大利亚和新西兰关于 COVID-19 大流行期间淋巴瘤、慢性淋巴细胞白血病和骨髓瘤管理的共识声明 2020

2020-07-15 Intern Med J . 2020 Jun;50(6):667-679.

COVID-19 大流行对血液系统恶性肿瘤患者的护理提出了独特的挑战。众所周知，病毒性肺炎会在癌症患者中引起不成比例的严重疾病，淋巴瘤、骨髓瘤和慢性淋巴细胞白血病患者很可能面临与 COVID-19 相

中文标题：

发布机构：

发布日期：

2020-07-15

简要介绍：

COVID-19 大流行对血液系统恶性肿瘤患者的护理提出了独特的挑战。众所周知，病毒性肺炎会在癌症患者中引起不成比例的严重疾病，淋巴瘤、骨髓瘤和慢性淋巴细胞白血病患者很可能面临与 COVID-19 相关的严重疾病的特殊风险。本声明是根据澳大利亚和新西兰作者的共识制定的。我们旨在为在 COVID-19 大流行期间做出个体患者决定的临床医生提供支持性指导，尤其是在获得医疗资源可能有限的时期。一般建议包括尽量减少患者接触 COVID-19 的建议，包括使用远程医疗、避免不必要的就诊以及尽量减少患者在输液室和其他临床领域的时间。该声明还提供了在 COVID-19 大流行期间评估治疗适应症、减少治疗相关的免疫抑制和减少特定血液系统恶性肿瘤患者的医疗保健利用的适当建议。关于血液系统恶性肿瘤治疗的具体决定需要根据疾病风险、免疫抑制风险、COVID-19 的社区传播率和可用的当地医疗资源进行个体化。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=4136a1c00213081b, title=澳大利亚和新西兰关于 COVID-19 大流行期间淋巴瘤、慢性淋巴细胞白血病和骨髓瘤管理的共识声明 2020, enTitle=, guiderFrom=Intern Med J . 2020 Jun;50(6):667-679., authorId=0, author=, summary=COVID-19 大流行对血液系统恶性肿瘤患者的护理提出了独特的挑战。众所周知，病毒性肺炎会在癌症患者中引起不成比例的严重疾病，淋巴瘤、骨髓瘤和慢性淋巴细胞白血病患者很可能面临与 COVID-19 相, cover=, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Jul 15 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=COVID-19 大流行对血液系统恶性肿瘤患者的护理提出了独特的挑战。众所周知，病毒性肺炎会在癌症患者中引起不成比例的严重疾病，淋巴瘤、骨髓瘤和慢性淋巴细胞白血病患者很可能面临与 COVID-19 相关的严重疾病的特殊风险。本声明是根据澳大利亚和新西兰作者的共识制定的。我们旨在为在 COVID-19 大流行期间做出个体患者决定的临床医生提供支持性指导，尤其是在获得医疗资源可能有限的时期。一般建议包括尽量减少患者接触 COVID-19 的建议，包括使用远程医疗、避免不必要的就诊以及尽量减少患者在输液室和其他临床领域的时间。该声明还提供了在 COVID-19 大流行期间评估治疗适应症、减少治疗相关的免疫抑制和减少特定血液系统恶性肿瘤患者的医疗保健利用的适当建议。关于血液系统恶性肿瘤治疗的具体决定需要根据疾病风险、免疫抑制风险、COVID-19 的社区传播率和可用的当地医疗资源进行个体化。, tagList=[TagDto(tagId=412, tagName=淋巴瘤), TagDto(tagId=1168, tagName=B细胞淋巴瘤)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=9, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2772, appHits=27, showAppHits=0, pcHits=226, showPcHits=2745, likes=0, shares=2, comments=3, approvalStatus=1, publishedTime=Fri Jul 16 18:48:59 CST 2021, publishedTimeString=2020-07-15, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Fri Jul 16 18:48:37 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Tue Jan 02 04:34:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])

66.pdf

下载请点击：

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1186426, encodeId=52d5118642687, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Thu Jan 20 13:22:03 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000133, encodeId=d75b100013333, content=学习了谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 20:14:00 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000107, encodeId=4e80100010e86, content=看看去谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 20:07:51 CST 2021, time=2021-07-16, status=1, ipAttribution=)]
2022-01-20 gujie_happy

学习！

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1186426, encodeId=52d5118642687, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Thu Jan 20 13:22:03 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000133, encodeId=d75b100013333, content=学习了谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 20:14:00 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000107, encodeId=4e80100010e86, content=看看去谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 20:07:51 CST 2021, time=2021-07-16, status=1, ipAttribution=)]
2021-07-16 ms2658711348342440

学习了谢谢

76 0
[GetPortalCommentsPageByObjectIdResponse(id=1186426, encodeId=52d5118642687, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Thu Jan 20 13:22:03 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000133, encodeId=d75b100013333, content=学习了谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 20:14:00 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000107, encodeId=4e80100010e86, content=看看去谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 20:07:51 CST 2021, time=2021-07-16, status=1, ipAttribution=)]
2021-07-16 ms2658711348342440

看看去谢谢

86 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

血液科指南

澳大利亚和新西兰关于 COVID-19 大流行期间淋巴瘤、慢性淋巴细胞白血病和骨髓瘤管理的共识声明 2020

相关指南

科室

工具

服务